A Study to Assess Real-world Outcomes for Long-Term Use of Guselkumab

The purpose of this study is to evaluate how long guselkumab remains in participants with moderate to severe crohn's disease (CD) or ulcerative colitis (UC) in real-world setting. CD and UC are Inflammatory bowel disease, a group of inflammatory conditions of the colon and small intestine.

NCT Number	NCT07532213
Lead Sponsor	Janssen-Cilag A.G., Switzerland
Conditions	Inflammatory Bowel Disease, Colitis, Ulcerative, Crohn Disease
Enrollment	50 participants
Start Date	2026-04-13
Primary Completion	2029-04-10 (estimated)
Study Completion	2029-04-10 (estimated)
Updated on ClinicalTrials.gov	2026-06-12